“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that pervasively affects the population across the world.
Currently, there is no effective treatment available for this and existing drugs merely slow the progression of cognitive function decline. Thus, massive effort is required to find an intended therapeutic target to overcome this condition.
The present study has been framed to investigate the ameliorative role of selective modulator of cannabinoid receptor type 2 (CB2), 1-phenylisatin in experimental AD condition…
Hence, this study concludes that CB2 receptor modulation can be a potential therapeutic target for the management of AD.”